---
layout: post
title: "Advisory Committee; Obstetrics, Reproductive and Urologic Drugs Advisory Committee; Renewal"
date: 2026-02-05 18:58:33 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-05973
original_published: 2022-03-23 00:00:00 +0000
significance: 8.00
---

# Advisory Committee; Obstetrics, Reproductive and Urologic Drugs Advisory Committee; Renewal

**Published:** February 05, 2026 18:58 UTC
**Source:** Federal Register
**Original Published:** March 23, 2022 00:00 UTC
**Document Number:** 2022-05973

## Summary

The Food and Drug Administration (FDA) is announcing the renewal of the Obstetrics, Reproductive and Urologic Drugs Advisory Committee (formerly known as the Bone, Reproductive and Urologic Drugs Advisory Committee) by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Obstetrics, Reproductive and Urologic Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the March 23, 2024, expiration date.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/03/23/2022-05973/advisory-committee-obstetrics-reproductive-and-urologic-drugs-advisory-committee-renewal)
- API: https://www.federalregister.gov/api/v1/documents/2022-05973

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
